Sei Investments Co. Buys 17,445 Shares of Glaukos Corporation $GKOS

Key Points

• Sei Investments Co. has increased its stake in Glaukos Corporation by 19.7%, now holding approximately 0.19% of the company valued at $10.4 million.
• Glaukos reported a revenue increase of 29.7% year-over-year to $124.12 million, with quarterly EPS beating expectations by $0.02.
• Analyst ratings for Glaukos vary, with one analyst rating it as a strong buy and several others maintaining buy or overweight ratings, indicating a market average rating of "Moderate Buy".

Sei Investments Co. increased its stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 19.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 106,135 shares of the medical instruments supplier's stock after acquiring an additional 17,445 shares during the period. Sei Investments Co. owned about 0.19% of Glaukos worth $10,446,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bessemer Group Inc. increased its holdings in Glaukos by 133.9% during the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 158 shares in the last quarter. Whipplewood Advisors LLC boosted its position in shares of Glaukos by 3,957.1% during the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 277 shares during the period. First Horizon Advisors Inc. grew its holdings in shares of Glaukos by 72.9% during the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock worth $37,000 after buying an additional 159 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of Glaukos by 583.9% during the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock worth $38,000 after buying an additional 327 shares in the last quarter. Finally, CoreCap Advisors LLC raised its position in Glaukos by 36.4% in the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock valued at $112,000 after buying an additional 200 shares during the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Stock Performance

Shares of Glaukos stock traded down $0.1340 during trading on Wednesday, hitting $90.8960. 666,860 shares of the stock were exchanged, compared to its average volume of 1,272,274. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average price of $96.48 and a 200-day moving average price of $102.34. The stock has a market capitalization of $5.21 billion, a price-to-earnings ratio of -55.09 and a beta of 0.78. Glaukos Corporation has a 1-year low of $77.10 and a 1-year high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. The business had revenue of $124.12 million during the quarter, compared to analysts' expectations of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.Glaukos's quarterly revenue was up 29.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. BTIG Research reaffirmed a "buy" rating on shares of Glaukos in a research report on Monday, July 14th. UBS Group boosted their price objective on shares of Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Wells Fargo & Company increased their target price on shares of Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Needham & Company LLC lowered their price target on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Finally, Truist Financial reissued a "buy" rating and set a $135.00 price target (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $127.42.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.